Literature DB >> 19455591

Use of the Patient Care Monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV.

Arthur C Houts1, Damon Lipinski, James P Olsen, Scott Baldwin, Murad Hasan.   

Abstract

OBJECTIVE: To evaluate the Patient Care Monitor (PCM1.0) Acute Distress and Despair normalized T scores as indicators of a diagnosis of Major Depression according to the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID).
METHODS: Subjects were 21 adult cancer patients identified by treating community oncologists as having significant emotional distress matched on age, cancer type, treatment history, and sex to 21 patients not having significant distress. All completed e/tablet PCM 1.0 and SCID administered by trained interviewers. Unweighted kappa and receiver operating characteristics (ROC) analyses were used to assess scale properties.
RESULTS: Agreement between SCID Major Depression and Acute Distress and Despair (T> or =65) were kappa=0.751 and 0.755, respectively. ROC area under the curve values for these two scales were 0.967 (SE+/-0.03) and 0.942 (SE+/-0.03), respectively, with optimal cut points of T=61 and 63, respectively.
CONCLUSIONS: Under conditions of preselected extreme groups, PCM 1.0 Acute Distress and Despair T scores are reasonable screening indicators of clinical depression in cancer patients. PCM 1.0 provides an efficient method for point-of-care screening of depression in community oncology clinics. Copyright 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 19455591     DOI: 10.1002/pon.1583

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  6 in total

1.  Real-world outcomes in patients with unresected stage III non-small cell lung cancer.

Authors:  Kellie J Ryan; Karen E Skinner; Ancilla W Fernandes; Rajeshwari S Punekar; Melissa Pavilack; Mark S Walker; Noam A VanderWalde
Journal:  Med Oncol       Date:  2019-01-31       Impact factor: 3.064

2.  Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Authors:  Mark S Walker; Edward J Stepanski; Carolina Reyes; Sacha Satram-Hoang; Arthur C Houts; Lee S Schwartzberg
Journal:  Ther Adv Hematol       Date:  2011-06

3.  Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer.

Authors:  Mark S Walker; Elaine Yu Pharm; Jiandong Kerr; Yeun Mi Yim; Edward J Stepanski; Lee S Schwartzberg
Journal:  BMC Res Notes       Date:  2012-06-20

4.  Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients.

Authors:  Mark S Walker; Murad Hasan; Yeun Mi Yim; Elaine Yu; Edward J Stepanski; Lee S Schwartzberg
Journal:  Health Qual Life Outcomes       Date:  2011-06-20       Impact factor: 3.186

Review 5.  Depression screening and patient outcomes in cancer: a systematic review.

Authors:  Anna Meijer; Michelle Roseman; Katherine Milette; James C Coyne; Michael E Stefanek; Roy C Ziegelstein; Erin Arthurs; Allison Leavens; Steven C Palmer; Donna E Stewart; Peter de Jonge; Brett D Thombs
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

6.  Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.

Authors:  Himani Aggarwal; Rajeshwari S Punekar; Li Li; Gebra Cuyun Carter; Mark S Walker
Journal:  Health Qual Life Outcomes       Date:  2020-06-22       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.